Last year we remarked on the resilience and return of clinical trial momentum postpandemic, where we saw a 6% growth of total trials (22% excluding COVID-19 trials) in 2021. One year later, the roller coaster resumes as the healthcare industry continues to be influenced by the global economy and political climate. Big headline events — the Inflation Reduction Act, the ongoing Russo-Ukrainian war, harsh funding cuts and divestments in the biopharma sector, and stalled economic growth in China — are just a few headwinds the healthcare industry braved in 2022. As the world picks up the pace to rebuild momentum and put the pandemic behind it, navigating through the evolving regulatory guidance and market dynamics calls for endurance and perseverance.

As with each edition of our Clinical Trials Roundup, we focus on an overview of the Phase I–III clinical trials that initiated in the prior calendar year (2022) across all therapeutic areas comprehensively covered by Trialtrove, as well as in-depth analyses into the key diseases, players, and geographies that impact the pharmaceutical industry. We will also look at any lingering effect of the pandemic, recovery, and challenges of adapting to the new equilibrium. 

For the full report, please download the PDF version at the top of this page.